
|Videos|November 15, 2021
Goals of ProsTIC's theranostics research in prostate cancer
Author(s)Urology Times staff
“We hope to further investigate next-generation PSMA-targeting molecules, develop new biomarkers to try to predict and monitor response to these novel therapies, optimize combinations with other treatments, and do some discovery research, including artificial intelligence [and] deep learning of our images,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
Advertisement
In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the goals and initiatives of the Prostate Cancer Theranostics and Imaging Center of Excellence (ProsTIC). Hofman is a nuclear medicine physician and director of ProsTIC, Melbourne, Australia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












